

IL-4 and IL-10 Antagonize IL-12-Mediated Protection Against Acute Vaccinia Virus Infection with a Limited Role of IFN- γ and Nitric Oxide Synthetase 2

This information is current as of August 4, 2022.

Maries van den Broek, Martin F. Bachmann, Gabriele Köhler, Marijke Barner, Rüdiger Escher, Rolf Zinkernagel and Manfred Kopf

J Immunol 2000; 164:371-378; ;
doi: 10.4049/jimmunol.164.1.371
<http://www.jimmunol.org/content/164/1/371>

References This article **cites 87 articles**, 54 of which you can access for free at:
<http://www.jimmunol.org/content/164/1/371.full#ref-list-1>

Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>

IL-4 and IL-10 Antagonize IL-12-Mediated Protection Against Acute Vaccinia Virus Infection with a Limited Role of IFN- γ and Nitric Oxide Synthetase 2¹

Maries van den Broek,* Martin F. Bachmann,[†] Gabriele Köhler,[‡] Marijke Barner,[†] Rüdiger Escher,[§] Rolf Zinkernagel,* and Manfred Kopf^{2†}

Resistance or susceptibility to most infectious diseases is strongly determined by the balance of type 1 vs type 2 cytokines produced during infection. However, for viruses, this scheme may be applicable only to infections with some cytopathic viruses, where IFN- γ is considered as mandatory for host defense with little if any participation of type 2 responses. We studied the role of signature Th1 (IL-12, IFN- γ) and Th2 (IL-4, IL-10) cytokines for immune responses against vaccinia virus (VV). IL-12^{-/-} mice were far more susceptible than IFN- γ ^{-/-} mice, and primary CTL responses against VV were absent in IL-12^{-/-} mice but remained intact in IFN- γ ^{-/-} mice. Both CD4⁺ and CD8⁺ T cells from IL-12^{-/-} mice were unimpaired in IFN- γ production, although CD4⁺ T cells showed elevated Th2 cytokine responses. Virus replication was impaired in IL-4^{-/-} mice and, even more strikingly, in IL-10^{-/-} mice, which both produced elevated levels of the proinflammatory cytokines IL-1 α and IL-6. Thus, IL-4 produced by Th2 cells and IL-10 produced by Th2 cells and probably also by macrophages counteract efficient anti-viral host defense. Surprisingly, NO production, which is considered as a major type 1 effector pathway inhibited by type 2 cytokines, appears to play a limited role against VV, because NO synthetase 2-deficient mice did not show increased viral replication. Thus, our results identify a new role for IL-12 in defense beyond the induction of IFN- γ and show that IL-4 and IL-10 modulate host protective responses to VV. *The Journal of Immunology*, 2000, 164: 371–378.

CD4⁺ (Th) cells can be divided into at least two subsets of effector cells, termed Th1 and Th2, with contrasting cytokine profiles. Immune responses are often polarized, as cytokine secretion from one subset inhibits the development of the other (1). The distinctive cytokine profiles can be correlated well with functional differences of the two subsets, which has provided a concept for how the immune system combats such diverse pathogens as bacteria, protozoa, fungi, and helminthic parasites (2).

Anti-viral defense has been less dominated by the Th1-Th2 paradigm, because CD8⁺ effector T cells are key mediators for clearance of noncytopathic viruses through cytolysis of infected cells and for clearance of cytopathic viruses through secretion of IFN- γ and TNF- α , which exert direct anti-viral activity (3, 4). Depending on the type of virus infection, CD4⁺ T cells promote protection by providing help for B cells (3) and CTL responses (5, 6). In addition, a role of CD4⁺ subpopulations (Th1 vs Th2) has been suggested, but is less well defined. For example, poliovirus-specific Th1 clones mediate protective immunity against a lethal poliovirus infection in a transgenic mouse model of poliomyelitis (7). CD4⁺ T cells and IFN- γ can effectively clear mouse CMV infection in the absence of CD8⁺ T cells (8–10). Similarly, influenza virus

infection can be cleared in the absence of CD8⁺ T cells (11), and Th1-specific anti-influenza clones protect against infection, whereas Th2 clones exacerbate pulmonary pathology (12). During measles virus infection, T cells show a biased Th2 response, which can be explained by the ability of the virus to suppress cell-mediated immunity and IL-12 production of dendritic cells and monocytes (13, 14). A prominent example is the case of HIV infection, where progression to AIDS may be associated with a Th1 to Th2 switch in a subset of patients (15, 16). In all of these examples, it has been suggested that Th1 responses promote viral clearance. IL-12 is the key cytokine for the induction of Th1 development (17), and IL-12 treatment has been shown to promote protective immunity to a variety of viruses including encephalomyocarditis virus (18), murine CMV (19), murine AIDS virus (20), lymphocytic choriomeningitis virus (LCMV)³ (21), and hepatitis B virus (22). In contrast, experiments with IL-12^{-/-} mice showed that endogenous IL-12 is not required for the control of mouse hepatitis virus (23) and LCMV infection (24).

Cell-mediated immune responses to microbial pathogens can be inhibited by Th2 cells. The best studied example is infection with *Leishmania major*, where IL-4 is responsible for fatal disease in susceptible BALB/c mice. Studies with viral infection systems have shown that overexpression of IL-4 using either recombinant vaccinia virus (VV) as a vector, IL-4 transgenic mice, or treatment with recombinant IL-4 was detrimental for the host during infection with VV (25), respiratory syncytial virus (26), and influenza virus (27). Further, transfer of influenza-specific Th2 clones delays virus clearance and exacerbates pulmonary pathology (12). Interestingly, several studies with IL-4^{-/-} mice have failed to support a role of this cytokine in viral pathology (28–30).

*Institute for Experimental Immunology, Zürich, Switzerland; [†]Basel Institute for Immunology, Basel, Switzerland; [‡]Department of Pathology, University of Freiburg, Freiburg, Germany; and [§]Max Planck Institute for Immunobiology, Freiburg, Germany

Received for publication March 2, 1999. Accepted for publication October 20, 1999.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ The Basel Institute for Immunology has been founded and is supported by Hoffmann-La Roche.

² Address correspondence and reprint requests to Dr. Manfred Kopf, Basel Institute for Immunology, Grenzacherstr. 487, 4005 Basel, Switzerland. E-mail address: Kopf@bii.ch

³ Abbreviations used in this paper: LCMV, lymphocytic choriomeningitis virus; VV, vaccinia virus; NOS2, NO synthetase 2; WR, Western Reserve strain of VV.

IL-10, a cytokine secreted mainly by Th2 cells and macrophages, is a potent inhibitor of the inflammatory response and Th1 polarization during bacterial and parasitic diseases. Hardly anything is known about the role of IL-10 during virus infections, although the incorporation of the human IL-10 gene into the EBV genome (31) suggests that this cytokine may be important for the virus to evade host defense. However, the few studies that addressed this issue suggested that IL-10 does not interfere with virus clearance (32, 33).

Type 1 and type 2 cytokines have been shown to differentially regulate NO production. The release of NO by activated macrophages and neutrophils is one of the major defense weapons against many pathogens (34) including a number of viruses such as ectromelia virus (35), HSV (36), EBV (37), and coxsackie virus (38). However, the role of NO during VV infection appears intriguing. While NO can interrupt VV replication (39), and a recombinant VV encoding NO synthetase 2 (NOS2) is highly attenuated (40), pharmacologic inhibition of NO during VV infection does not alter the course of infection (41). Because pharmacologic inhibitors also affect NOS1 and NOS3, a detailed study on the role of NOS2 in combination with its major cytokine regulators remains to be done.

In this study, we have analyzed effector responses and virus clearance in C57BL/6 mice deficient for key type 1 cytokines (IL-12, IFN- γ) and type 2 cytokines (IL-4, IL-10), and for inducible NO synthase following infection with VV. VV is the representative member of the poxvirus family of cytoplasmic DNA viruses. VV induces cytolytic infections and is an expert in exploiting the cytokine network for immune evasion (42). Our results demonstrate that endogenous type 1 and type 2 cytokine responses cross-regulate immunity to acute VV infection with IL-12 and IL-10 as the dominant factors for resistance and susceptibility, respectively.

Materials and Methods

Mice

IL-4^{-/-} mice (43), IL-10^{-/-} mice (44) (kindly provided by W. Müller, Cologne, Germany), IFN- γ ^{-/-} mice (45) (kindly provided by Genentech, South San Francisco, CA), IL-12p35^{-/-} mice (46) (kindly provided by J. Magram, Nutley, NJ), and NOS2^{-/-} mice (47) (kindly provided by M. Modollel with the permission of J. Mudgett) were generated as described. Mutant mouse strains used for the experiments were back-crossed for six to eight generations to C57BL/6. Genotypes were determined by PCR amplification of DNA prepared from tail biopsies with specific oligonucleotide primers for IL-4 (forward, GTG AGC AGA TGA CAT GGG GC; reverse, CTT CAA GCA TGG AGT TTT CCC), IL-10 (forward, CAA AGC CAC AAG GCA GCC TTG; reverse, GAC AGT GCT AGA GCC CGG AGT), IFN- γ (forward, AGA AGT AAG TGG AAG GGC CCA GAA G; reverse, AGG GAA ACT GGG AGA GGA GAA ATA T), IL-12p35 (wild-type allele: forward, AGC TCC TCT CAG TGC CGG TC; reverse, GGT CTT CAG CAG GTT TCG GG; mutant allele: forward, GGC TCT GGA CTC ACC TGG AT; reverse, GCA TCG CAT TGT CTG AGT AGG), NOS2 (wild-type allele: forward, TCA CGC TTG GGT CTT GTT CAC; reverse, CAG GTC ACT TTG GTA GGA TTT; mutant allele: forward, GCA ATG TGA CAA AGC TCC TTC AG; reverse, GAA GAA CGA GAT CAG CAG CCT C). Mice were maintained in a facility free of specific pathogens at the Basel Institute for Immunology. C57BL/6 wild-type mice were purchased from IFFA-Credo (Saint Germain-sur-l'Abresle, France). For experiments, 8- to 12-wk-old female mice were used and kept in microisolator cages. At the time of experiments, 8-wk-old IL-10^{-/-} mice showed no obvious signs of colitis.

Viruses and virus titration

VV strain Western Reserve (WR) and recombinant VV expressing either murine IL-4 (25), murine IFN- γ (48), or the LCMV glycoprotein (VV-G2) were grown at a low multiplicity of infection on BSC40 cells and plaqued on BSC40 cells. VV-IL-4 and VV-IFN- γ were kindly provided by A. Ramsay (Canberra, Australia). VV-G2 was used as a control recombinant VV, because G2 derived from LCMV is irrelevant for the anti-VV response.

Mice were infected with 2×10^6 pfu VV i.p., unless stated otherwise, and sacrificed by CO₂. For determination of viral titers, lungs and ovaries were frozen at indicated days of harvest from mice and then thawed and homogenized in 2 ml MEM plus 2% FCS just before use in plaque assays. Tenfold dilutions were plaqued on monolayers of BSC40 cells in 24-well plates. Plates were stained after 48 h with crystal violet, and plaques were counted.

Cytotoxic T cell assay

Six days after infection, spleens were taken out and a single-cell suspension was made. Splenocytes were adjusted to 9×10^6 cells/ml. Target cells (MC57G H-2^b fibroblasts) were infected with VV-WR (multiplicity of infection, 3) for 3 h at 37°C. During the last 90 min of the infection, ⁵¹Cr-NaCrO₄ was added. Threefold dilutions of effector cells were incubated for 6 h at 37°C with 10^4 target cells in 200- μ l cultures. The percentage specific ⁵¹Cr release was calculated as: % specific lysis = [(experimental release - spontaneous release)/(maximum release - spontaneous release)] \times 100%.

Separation and stimulation of cells

Spleens were removed at day 7 after infection, teased to single-cell suspensions, and CD4⁺ and CD8⁺ (mAb 53-6.72) T cells were purified by magnetic cell separation (MACS; Miltenyi Biotec, Bergisch-Gladbach, Germany). Cells were incubated with CD4 mAb or CD8 mAb coupled to magnetic beads according to the manufacturer's instructions and sorted using MACS columns and the MidiMACS system. Aliquots of the unsorted and sorted cell fractions were analyzed by flow cytometry. CD4⁺ and CD8⁺ T cell populations were sorted to a purity of 80-90%. Cells were kept on ice until further use for in vitro cell culture. Purified cell populations and unsorted splenocytes from infected mice were plated ($2 \times 10^5/0.2$ ml) in flat-bottom microtiter plates (Costar, Cambridge, MA) precoated with anti-CD3 mAb 145-2C11 (10 μ g/ml) and cultured for 48 h. Cytokine levels in the supernatant were determined by sandwich ELISA for IL-4, IL-10, IFN- γ (PharMingen, San Diego, CA), IL-1 α , and IL-6 (Genzyme, Cambridge, MA).

Histology

On day 6 after infection, lungs were isolated, fixed in 4% neutral buffered formalin, and paraffin embedded. Tissue sections (5 μ m) were stained with hematoxylin and eosin and analyzed microscopically. Photographs were taken with a Zeiss Axiophoto photomicroscope (Zeiss, Oberkochen, Germany).

Results

IL-12 is more important than IFN- γ for clearance of VV infection

To study the role of key type 1 cytokines on the susceptibility to infection with a cytopathic DNA virus, IL-12p35^{-/-} mice, IFN- γ ^{-/-} mice, and C57BL/6 wild-type controls were infected with 10^6 pfu VV (WR), and virus titers were determined in ovaries, where VV replicates most extensively. VV clearance was markedly impaired in IL-12^{-/-} mice, which showed a 20-fold and 100-fold increased viral load at days 3 and 6 after infection as compared with controls (Fig. 1). Virus titers were also highly elevated (10- to 20-fold) after infection with low-dose (10^4 pfu) VV (WR) (not shown). In contrast, clearance of VV (WR) was not severely affected in IFN- γ ^{-/-} mice throughout the course of infection (Fig. 1). Interestingly, after infection with a recombinant VV (VV-G2) (see Fig. 4), which is attenuated due to a targeted mutation of the thymidine kinase gene, virus titers in ovaries of IFN- γ ^{-/-} mice were \sim 10- to 50-fold increased compared with controls. Thus, our results demonstrate the IL-12 response to VV infection (25) is crucial for host defense, whereas IFN- γ appears neither required for virus clearance nor for the induction and reinforcement of this IL-12 response. However, dependent on the virulence of infection, IFN- γ can contribute to anti-viral immunity.





FIGURE 1. Impaired clearance of VV in IL-12^{-/-} mice. Mice were infected i.p. with 10⁶ pfu of VV (WR) and sacrificed on days 3 and 6 to collect ovaries for determination of virus titers. Shown are values of individual mice. Data are representative of three separate experiments.

Endogenous IL-4 and IL-10 inhibit clearance of VV infection

It has been well established that IL-4 and IL-10 can inhibit type 1 responses and prevent clearance of some pathogens (2). To assess the role of these cytokines during infection with VV, we measured virus titers in ovaries of IL-4^{-/-} mice, IL-10^{-/-} mice (both C57BL/6), and wild-type mice infected with varying doses (10⁴, 10⁶, and 10⁸ pfu) of VV (WR) or with 10⁶ pfu of recombinant VV-G2. A dose of 10⁸ pfu was lethal for wild-type mice (3/3) and for IL-4^{-/-} mice (2/3). In contrast, IL-10^{-/-} mice showed a dramatically reduced virus titer ranging between 10³- to 10⁴-fold after infection with low, intermediate, and high doses of VV (WR) and VV-G2 at day 6 after infection (Fig. 2). Virus titers were reduced 10- to 20-fold as early as day 3 after infection. In IL-4^{-/-} mice, virus titers in ovaries were reduced 80-fold after infection with 10⁶ pfu VV (WR), whereas virus replication was not significantly different after infection with low doses (10⁴ pfu) of VV (WR) or with 10⁶ pfu of VV-G2 (Fig. 2). These results demonstrate that endogenous IL-4 and, in particular, IL-10 inhibit VV clearance. IL-4 production depends mainly on differentiated type 2 effector T cells producing a panel of type 2 cytokines including IL-10, suggesting that IL-4 may be important later in infection during the acquired response. In contrast, IL-10 can be produced by, and act as an autocrine inhibitor of, macrophages early after infection, which may explain the finding that IL-10 is more potent than IL-4 in suppression of host defense.

FIGURE 2. Enhanced clearance of VV in IL-4^{-/-} and IL-10^{-/-} mice. Mice were infected i.p. with doses indicated of VV (WR) and VV-G2 and sacrificed on days 3 and 6 to collect ovaries for determination of virus titers. Shown are values of individual mice. Data are representative of two separate experiments.



IFN-γ production does not require IL-12

Studies with mice deficient for IL-4 (43), IL-4Rα (49, 50), and STAT6 (51–53), the IL-4-activated signal transducer, have demonstrated an important role for IL-4 in the development of Th2 cells. Vice versa, mice deficient for IL-12 (46), IL-12Rβ1 (54), and STAT4 (55, 56), the IL-12-activated signal transducer, highlighted a critical role of IL-12 in the development of IFN-γ-secreting Th1 cells. To determine cytokine patterns in virus-infected mice, we purified splenic CD4⁺ and CD8⁺ cells from infected mice and measured IL-4, IL-10, and IFN-γ production after restimulation with anti-CD3. As shown in Fig. 3A, C57BL/6 mice mounted a strong type 1 response with IFN-γ produced by both CD4⁺ and CD8⁺ T cells. IL-4 was produced by CD4⁺ T cells only, while IL-10 was secreted by CD4⁺ and to a lower extent also from CD8⁺ T cells. CD4⁺ T cells in IL-12^{-/-} mice showed augmented type 2 cytokine responses (e.g., IL-4 and IL-10), but also a slightly increased IFN-γ response. CD8⁺ T cell cytokine production was unaltered in the absence of IL-12. CD4⁺ T cells from IL-4^{-/-} mice produced lower amounts of IL-10 but normal IFN-γ, indicating impaired Th2 without reciprocal increase in Th1 development. In contrast, Th1 development was markedly increased in IL-10-deficient mice. Next, we examined CD4⁺ and CD8⁺ T cells from bronchoalveolar lavage of infected mice. As determined by intracellular staining, the frequency of IFN-γ-producing CD4⁺ T cells was unaltered in IL-4^{-/-} mice (Fig. 3B), but was considerably enhanced in IL-10^{-/-} mice and also slightly elevated in IL-12^{-/-} mice (Fig. 3B), essentially in consistency with measurements in supernatants from restimulated splenic CD4⁺ T cells. Thus, as might be predicted, we find enhanced Th1 development in the absence of IL-10 and impaired Th2 development in the absence of IL-4. Surprisingly, IFN-γ production was not significantly influenced by the absence of IL-12 or IL-4 after vaccinia infection.

To assess the production of proinflammatory cytokines, we measured IL-1α and IL-6 in supernatants after anti-CD3 stimulation of total splenocytes derived from groups of VV-infected mice. Both IL-4^{-/-} and IL-10^{-/-} mice showed markedly increased levels of both IL-1α and IL-6, (Fig. 3C), which demonstrates that both IL-4 and IL-10 are potent inhibitors of the proinflammatory cytokine response against VV.




FIGURE 3. Cytokine responses. **A**, Mice were infected i.p. with 2×10^6 pfu of VV (WR) and sacrificed on day 7 to collect spleens and the bronchoalveolar lavage (BAL) for determination of cytokine production. Splenic CD4⁺ T cells (upper panel) and CD8⁺ T cells (lower panel) were purified by magnetic sorting and stimulated with immobilized anti-CD3 for 48 h before measurement of supernatants for IL-4, IL-10, and IFN- γ by ELISA. Shown are values of individual mice (open symbols) and the average of a group (filled symbols). **B**, BAL cells were stimulated with PMA and ionomycin for 4 h. During the last 2 h Brefeldin was added to retain cytokines in the cytoplasm. Cells were stained with APC-labeled anti-CD4, FITC-labeled anti-CD8, and after permeabilization using saponin, with PE-labeled anti-IFN- γ (or IL-4) before analysis by three-color flow cytometry. Shown is the percentage of CD4⁺ and CD8⁺ T cells producing IFN- γ . The frequency of IL-4-producing cells was below detection limit and is not shown. **C**, Unpurified splenocytes were stimulated as described above, and supernatants were measured for IL-1 α and IL-6. Shown are average values ($n = 3$ /group) from two different experiments.

IL-4 expressed by recombinant VV affects virus clearance by inhibition of IL-12-dependent and IL-12-independent pathways

Ectopic expression of a cytokine exactly at the same time and place where the immune response against the virus is initiated




FIGURE 4. Mice were infected i.p. with 2×10^6 pfu of either VV-G2, VV-IL-4, or VV-IFN- γ and sacrificed on day 6 to collect ovaries for determination of virus titers. Shown are values of individual mice.

allows one to study the potential effect of this cytokine on the generation of specific immunity and the consequences for virus control in vivo (57). To further understand the role of type 1 and type 2 responses, the effector mechanisms, and their interrelation during infection with VV, we infected wild-type and cytokine-deficient mice with 10^6 pfu recombinant VV expressing IL-4 (VV-IL-4), IFN- γ (VV-IFN- γ), or an irrelevant control protein (VV-G2) and determined virus clearance (Fig. 4) and virus-specific CTL responses (Fig. 5). In agreement with others, we found that virus-expressed IL-4 exacerbates VV infection in mice (25). Virus titers in ovaries of C57BL/6 mice were 100- to 1000-fold increased (Fig. 4) and persisted much longer (>11 days, not shown). Increased viral load (3 log) and delayed clearance was also observed in IL-4^{-/-} mice, demonstrating that virus- but not host-encoded IL-4 inhibits virus clearance. Notably, virus titers in IL-12^{-/-} mice were higher after VV-IL-4 compared with VV-G2 infection, suggesting that IL-4 inhibits other host defense pathways in addition to inhibition of IL-12. In contrast, the susceptibility of IL-12^{-/-} and IFN- γ ^{-/-} mice to VV was almost entirely reverted by vector expressed IFN- γ (VV-IFN- γ).

CTL responses are abrogated in IL-12^{-/-} mice but not in IFN- γ ^{-/-} mice

To evaluate the role of type 1 and type 2 cytokines on the activity of antiviral CTL responses, IL-12^{-/-}, IFN- γ ^{-/-}, IL-10^{-/-}, and IL-4^{-/-} mice were infected with VV-G2 and primary ex vivo CTL responses were measured at day 6, the peak time of anti-VV CTL (Fig. 5). In agreement with others, we found that IFN- γ is not required for the generation of cytolytic effector cells during virus infection (30, 58, 59). Indeed, vaccinia-specific CTL responses were slightly elevated in IFN- γ ^{-/-} mice, which may be due to enhanced proliferation of T cells in the absence of IFN- γ (45, 59). In contrast, CTL responses were virtually abrogated in infected IL-12^{-/-} mice. IL-4^{-/-} and IL-10^{-/-} mice infected with recombinant VV-G2 showed little differences compared with wild-type mice. Basically the same results were obtained when the various cytokine-deficient mice were infected with VV (WR), with the exception of IL-4^{-/-} and IL-10^{-/-} mice that showed slightly (~ 3 -fold) enhanced CTL responses (data not shown). It has been suggested previously that IL-4 can suppress CD8⁺ T cell cytotoxicity in vitro and in vivo. In agreement with these results, we found that CTL responses were abolished in immunocompetent mice infected with VV-expressing IL-4 (VV-IL-4). Surprisingly, VV-IL-4 failed to suppress CTL responses in IL-4^{-/-} mice. In contrast, virus-expressed IFN- γ (VV-IFN- γ) reconstituted CTL responses to almost normal levels in IL-12^{-/-} mice, which may suggest that




FIGURE 5. VV-specific primary CTL responses. Mice were infected i.p. with 2×10^6 pfu of either VV-G2, VV-IL-4, or VV-IFN- γ and sacrificed on day 6 to collect spleens for determination of primary CTL activity by ^{51}Cr release assay using MC57G fibroblasts infected with VV as target cells. Lysis of uninfected MC57G targets was $<10\%$. Shown are values of the average of two mice. Data are representative of two separate experiments.

tissue damage and possibly CD8⁺ T cell exhaustion due to increased viral replication is responsible for the lack of measurable CTL responses in IL-12^{-/-} mice.

Severe morphological lung damage in IL-12^{-/-} mice

We next assessed the overall pulmonary inflammatory process of mice infected with VV. Therefore, lung tissues from virus-infected mice were analyzed histologically. Lung pathology in C57BL/6 mice infected with VV-G2 was confined to a few foci of perivascular and peribronchial inflammation of lymphocytes, mononuclear, and some polymorphonuclear cells (Fig. 6). In contrast, infection of C57BL/6 and IL-12^{-/-} mice with VV-IL-4 and VV-G2, respectively, profoundly altered the lung architecture, with extensive inflammation and edema, and with damage of alveoli.

NO is dispensable for clearance of VV

NO production has been shown to be beneficial as an anti-viral effector mechanism both in vitro and in vivo (34). Type 1 and type 2 cytokines are important regulators of NO production with antagonizing activities. IFN- γ and TNF- α are the main activators of NOS2, the enzyme that catalyzes NO production, whereas type 2 cytokines, i.e., IL-4, IL-10, and IL-13, are potent inhibitors. Thus, we hypothesized that the antagonizing effects of type 1 and type 2 cytokines on the control of VV infection may be mediated by regulation of NO production. To test the role of NO for clearance of acute VV infection, we studied NOS2^{-/-} mice infected with VV (WR). Viral growth in the ovaries was comparable in NOS2^{-/-} and C57BL/6 control mice at days 6 (Fig. 7), 8, and 10 (not shown), suggesting that NO production is not critical for control of VV infection.

Discussion

Our study demonstrates the first clear example where the balance of endogenous type 1 and type 2 cytokines produced in response to viral infection determines pathogen clearance and the severity of disease. IL-12^{-/-} and IFN- γ ^{-/-} mice were more susceptible, whereas IL-4^{-/-} and IL-10^{-/-} mice were more resistant, to VV infection compared with wild-type controls. IFN- γ is considered as a critical player in anti-viral immune responses, mainly based on its direct anti-viral activity (4). However, in vivo studies have demonstrated that the role of IFN- γ in anti-viral immune responses varies with the type and conditions of infection. Mice with a disrupted gene for IFN- γ R1 or IFN- γ , or mice treated with anti-IFN- γ Ab, develop increased susceptibility to VV (59), ectromelia virus (60), CMV (61), and mouse hepatitis virus (62, 63). In contrast,

control of acute infection with vesicular stomatitis virus (59), pseudorabies virus (63), γ -herpesvirus (64), and influenza virus (58) is not dependent on IFN- γ . Although IFN- γ is thought to be crucial




FIGURE 6. Characterization of lung pathology during VV infection. C57BL/6 (A and C) and IL-12^{-/-} mice (B) were infected i.p. with 2×10^6 pfu of either VV-G2 (A and B) or VV-IL-4 (C) and sacrificed on day 6 to collect lungs for histological evaluation. Sections were stained with hematoxylin and eosin.




FIGURE 7. Unaltered VV clearance of NOS2^{-/-} mice. Mice were infected i.p. with 2×10^6 pfu of VV (WR) and sacrificed on day 6 to collect ovaries for determination of virus titers. Shown are values of individual mice. Data are representative of two separate experiments.

for the control of VV (4), we found that endogenous IL-12 is superior to IFN- γ for virus clearance. IFN- γ ^{-/-} mice showed significantly increased susceptibility only to infection with VV strains of low virulence such as VV (Lancy) (65) or recombinant VV (i.e., VV-G2, with a mutation of the tk gene). Clearance of a strain with high virulence in mice was minimally affected by the absence of IFN- γ . In contrast, IL-12-deficient mice were much more susceptible, independent of the virulence of the VV strain. It has been shown that IL-12 treatment is beneficial for the host during infection with a variety of viruses, and that this effect is mediated primarily through induction of IFN- γ by NK cells and T cells (18, 20, 66, 67). Our results expand the host defense repertoire of IL-12 beyond the induction of IFN- γ , the most widely studied antimicrobial action of IL-12 (68). In addition to inducing IFN- γ , IL-12 has been shown to stimulate expression of TNF- α (69), which can act by itself in the absence of IFN- γ in the control of visceral leishmaniasis (70). An important role of TNF- α and the two receptors TNFR-1 (p55) and TNFR-2 (p75) in the control of VV replication has been demonstrated (57).

CTL responses were abrogated in IL-12^{-/-} mice but remained normal in IFN- γ ^{-/-} mice after VV infection. These findings are in concordance with those of others, who showed that *in vitro* CTL generation was augmented by the addition of IL-12 in the presence of neutralizing anti-IFN- γ Abs (71). Unimpaired CTL generation observed in IL-12^{-/-} mice after immunization with allogeneic cells (46) or with LCMV (M. van den Broek, unpublished observations) probably reflects the inability of these stimuli to induce significant IL-12 levels *in vivo* (72) and an IL-12-independent pathway for the induction of CTL responses. High and low susceptibility to VV correlates with the absence and presence of CTL responses in IL-12^{-/-} and IFN- γ ^{-/-} mice, respectively. This may argue that defective CTL responses allow uncontrolled VV replication in IL-12^{-/-} mice. However, protection against acute and challenge infection with VV, vesicular stomatitis virus, and Semliki Forest virus (SFV) has been shown to be independent of both perforin- and fas-dependent pathways suggesting that CD8⁺ T cell cytotoxicity plays a limited if any role after infection with cytopathic viruses (73).

Excess of IL-4 has been shown to be deleterious for the host in various virus models (25, 27, 29). In particular, overexpression of IL-4 at the site of infection using VV as a vector severely inhibits host defense (25). In agreement with these results, we found that C57BL/6 mice infected with recombinant VV-IL-4 developed lung pathology and virus titers similar to IL-12^{-/-} mice infected with VV expressing an irrelevant control protein, suggesting that IL-12-mediated protection is inhibited by IL-4. However, the finding that VV-expressed IL-4 further increased viral spread in IL-12^{-/-}

mice argues that IL-4 has detrimental effects independent of IL-12 inhibition. Importantly, at physiological levels, IL-4 appears to play a more limited role as an inhibitor of VV clearance, which is dependent on the dose and virulence of the VV inoculate. Virus titers were significantly decreased in IL-4^{-/-} mice infected with intermediate but not with low or high doses of VV (WR). Furthermore, infection with less virulent VV strains such as VV (Lancy) (28) or recombinant derivatives (i.e., VV-G2) showed no evident role for IL-4 in suppression of virus replication. Interestingly, we found that the absence of IL-10 promoted the host defense much stronger than the absence of IL-4. IL-10^{-/-} mice showed markedly diminished virus titers independent of the dose and virulence of VV inoculate. Paradoxically, infection of mice with a recombinant VV-expressing murine IL-10 resulted in subtle *in vivo* differences (32). IL-10 is known as a potent inhibitor of proinflammatory cytokines and IL-12 production by both macrophages and dendritic cells *in vitro* (74, 75) and *in vivo* (76, 77). In agreement with this, we demonstrated that splenocytes of VV-infected IL-10^{-/-} mice produced augmented levels of the proinflammatory cytokines IL-1 and IL-6. Splenocyte cultures of infected IL-4^{-/-} mice also contained elevated levels of the two proinflammatory cytokines, which have been shown to be important for VV clearance (78). *In vivo*, IL-10 is probably a more effective inhibitor of VV clearance compared with IL-4, because it is secreted by activated macrophages and can act as an autocrine inhibitor immediately after infection, whereas IL-4 is produced mainly by Th2 cells that develop later in infection.

Based on the findings that NO production is induced by type 1 cytokines (e.g., IFN- γ) and inhibited by type 2 cytokines (IL-4, IL-10, IL-13, TGF- β) (34), we hypothesized that the difference in susceptibility of IL-12^{-/-} and IFN- γ ^{-/-} vs IL-4^{-/-} and IL-10^{-/-} mice can be explained by altered regulation of NO. In fact, NO excess has been demonstrated to inhibit VV replication *in vitro* (39) and *in vivo* (40). Surprisingly, our results demonstrate that NOS2-deficient mice cleared VV as well as controls, which is in agreement with others showing that pharmacologic inhibition of NO during VV infection did not alter the course of infection (41). This argues that NO can exhibit potent anti-viral activity if expressed locally by recombinant VV, whereas it plays a limited if any role during the normal course of VV infection. Our results suggest that altered reactive nitrogen intermediates are not responsible for the susceptibility and the resistance of IL-12- and IL-10-deficient mice, respectively, to VV infection. The role of reactive oxygen intermediates in this scenario remains to be tested.

Immune responses to viruses are dominated by Th1 cells that provide help for anti-virus IgG2a responses and CTLs that kill infected cells. In general, virus-specific CD8⁺ T cells produce the Th1-like cytokine pattern, i.e., IFN- γ , LT- α , and TNF- α , and these have been referred to as Tc1 cells. IL-12 has been shown to be a critical factor for the development of Th1 cells in response to bacteria and parasites (17, 79). Less is known about the role of IL-12 for Th1 and Tc1 development after viral infection. A variety of viruses have been shown to transiently increase the IL-12p40 gene or stimulate IL-12p70 production shortly after infection (80–82). However, IL-12^{-/-} mice infected with mouse hepatitis virus (23) or LCMV (24) show unaltered IFN- γ and IL-4 responses in both CD4⁺ and CD8⁺ T cells. Our data demonstrate that IL-12 is dispensable for the development of both IFN- γ -producing CD4⁺ and CD8⁺ T cells after VV infection and that these cells also migrate to sites of virus replication. In contrast, in the absence of IL-12, we did find elevated Th2 cytokine production (i.e., IL-4 and IL-10) after VV infection. Previously it has been suggested that the presence of IL-4 can induce secretion of type 2 cytokines by CD8⁺ T cells, which remain cytolytic or switch to noncytolytic Th cells

dependent on the experimental system (83, 84). Our present results suggest that CD8⁺ Tc2 differentiation after viral infection is limited even when conditions appear favorable, i.e., the absence of IL-12 and elevated IL-4 secretion by CD4⁺ T cells. Moreover, our results confirm that effector CD8⁺ T cell cytolytic function appears not to be markedly affected by endogenous IL-4 levels as has been shown for VV, LCMV, and Sendai virus infection (28, 30), although the potential of IL-4, when present in excess, to inhibit CTL responses was evident after infection with recombinant VV-expressing IL-4 (25) or in IL-4 transgenic mice infected with respiratory syncytial virus (29). Inhibition of CTL by endogenous IL-4 may be more important during memory responses, as demonstrated for respiratory syncytial virus (85).

Together our studies exemplify cytokine-mediated control of a cytopathic virus. IL-12 plays a dominant role in protective immunity to acute VV. IL-12 activity goes beyond the induction of IFN- γ and includes control of CTL responses and probably innate immunity, such as the production of inflammatory cytokines (e.g., TNF- α) and chemokines. These results warrant further studies with other cytolytic viruses such as influenza, which can be effectively controlled in the absence of IFN- γ (58). Endogenous IL-4 and, in particular, IL-10 responses interfere with immunity to VV, which can be explained by inhibition of the monokines IL-1, IL-6, and IL-12. Excessive amounts of IL-4 expressed by recombinant VV shows a more dramatic role than its absence during infection. Overexpression of IFN- γ by recombinant VV at the site of infection cures susceptible IL-12^{-/-} mice (Fig. 4) and nude mice (4), demonstrating the potent direct anti-viral activity of IFN- γ . However, endogenous IFN- γ production is not crucial for control of VV replication. Interestingly, studies with recombinant VV vectors expressing IL-2 (86), TNF- α (87), CD40L (88), and NOS2 (40) have all suggested a critical role for these factors in resistance to VV. However, mice deficient for these genes cleared VV normally (28, 57, 89) (Fig. 7). In contrast, the role of endogenous IL-10 as an inhibitor of virus clearance was undiscovered in studies with recombinant VV-expressing IL-10. These results are important for understanding the role of type 1 and type 2 cytokines during infection with cytopathic viruses and for cytokine viral vector-based gene therapy and vaccination approaches.

Acknowledgments

We thank A. Ramsay and I. Ramshaw for VV-IL-4 and VV-IFN- γ , B. Ecabert, K. Lefrang, and C. Olsson for excellent technical assistance, and Phillip Scott and Ed Palmer for critical reading of the manuscript.

References

- Seder, R. A., and W. E. Paul. 1994. Acquisition of lymphokine-producing phenotype by CD4⁺ T cells. *Annu. Rev. Immunol.* 12:635.
- Abbas, A. K., K. M. Murphy, and A. Sher. 1997. Functional diversity of helper T lymphocytes. *Nature* 383:787.
- Zinkernagel, R. M. 1996. Immunology taught by viruses. *Science* 271:173.
- Ramsay, A. J., J. Ruby, and I. A. Ramshaw. 1993. A case for cytokines as effector molecules in the resolution of virus infection. *Immunol. Today* 14:155.
- Bennink, J. R., and P. C. Doherty. 1978. Different rules govern help for cytotoxic T cells and B cells. *Nature* 276:829.
- Zinkernagel, R. M., G. N. Callahan, A. Althage, S. Cooper, J. W. Streilein, and J. Klein. 1978. The lymphoreticular system in triggering virus plus self-specific cytotoxic T cells: evidence for T help. *J. Exp. Med.* 147:897.
- Mahon, B. P., K. Katrak, A. Nomoto, A. J. Macadam, P. D. Minor, and K. H. Mills. 1995. Poliovirus-specific CD4⁺ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor. *J. Exp. Med.* 181:1285.
- Jonjic, S., W. Mutter, F. Weiland, M. Reddehase, and U. Koszinowski. 1989. Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4⁺ T lymphocytes. *J. Exp. Med.* 169:1199.
- Jonjic, S., I. Pavic, P. Lucin, D. Rukavina, and U. Koszinowski. 1990. Efficacious control of cytomegalovirus infection after long-term depletion of CD8⁺ T lymphocytes. *J. Virol.* 64:5457.
- Lucin, P., S. Jonjic, M. Messerle, B. Polic, H. Hengel, and U. Koszinowski. 1994. Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon- γ and tumour necrosis factor. *J. Gen. Virol.* 75:101.
- Eichelberger, M., W. Allan, M. Zijlstra, R. Jaenisch, and P. C. Doherty. 1991. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8⁺ T cells. *J. Exp. Med.* 174:875.
- Graham, M. B., V. L. Braciale, and T. J. Braciale. 1994. Influenza virus-specific CD4⁺ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. *J. Exp. Med.* 180:1273.
- Fugier-Vivier, I., C. Servet-Delprat, P. Rivallier, M. C. Rissoan, Y. J. Liu, and C. Rabourdin-Combe. 1997. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. *J. Exp. Med.* 186:813.
- Karp, C. L., M. Wysocka, L. M. Wahl, J. M. Ahearn, P. J. Cuomo, B. Sherry, G. Trinchieri, and D. E. Griffin. 1996. Mechanism of suppression of cell-mediated immunity by measles virus. [Published erratum appears in 1997 *Science* 275:1053.] *Science* 273:228.
- Clerici, M., and G. M. Shearer. 1993. A TH1 \rightarrow TH2 switch is a critical step in the etiology of HIV infection. *Immunol. Today* 14:107.
- Barker, E., C. E. Mackewicz, and J. A. Levy. 1995. Effects of TH1 and TH2 cytokines on CD8⁺ cell response against human immunodeficiency virus: implications for long-term survival. *Proc. Natl. Acad. Sci. USA* 92:11135.
- Hsieh, C. S., S. E. Macatonia, C. S. Tripp, S. F. Wolf, A. O'Garra, and K. M. Murphy. 1993. Development of TH1 CD4⁺ T cells through IL-12 produced by *Listeria*-induced macrophages. *Science* 260:547.
- Ozmen, L., M. Aguet, G. Trinchieri, and G. Garotta. 1995. The in vivo antiviral activity of interleukin-12 is mediated by γ interferon. *J. Virol.* 69:8147.
- Orange, J. S., B. Wang, C. Terhorst, and C. A. Biron. 1995. Requirement for natural killer cell-produced interferon γ in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. *J. Exp. Med.* 182:1045.
- Gazzinelli, R. T., N. A. Giese, and H. C. R. Morse. 1994. In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). *J. Exp. Med.* 180:2199.
- Orange, J. S., S. F. Wolf, and C. A. Biron. 1994. Effects of IL-12 on the response and susceptibility to experimental viral infections. *J. Immunol.* 152:1253.
- Cavanaugh, V. J., L. G. Guidotti, and F. V. Chisari. 1997. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. *J. Virol.* 71:3236.
- Schijns, V. E., B. L. Haagmans, C. M. Wierda, B. Kruihof, I. A. Heijnen, G. Alber, and M. C. Horzinek. 1998. Mice lacking IL-12 develop polarized Th1 cells during viral infection. *J. Immunol.* 160:3958.
- Oxenius, A., U. Karrer, R. M. Zinkernagel, and H. Hengartner. 1999. IL-12 is not required for induction of type 1 cytokine responses in viral infections. *J. Immunol.* 162:965.
- Sharma, D. P., A. J. Ramsay, D. J. Maguire, M. S. Rolph, and I. A. Ramshaw. 1996. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. *J. Virol.* 70:7103.
- Graham, M. B., and T. J. Braciale. 1997. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. *J. Exp. Med.* 186:2063.
- Moran, T. M., H. Isobe, A. Fernandez-Sesma, and J. L. Schulman. 1996. Interleukin-4 causes delayed virus clearance in influenza virus-infected mice. *J. Virol.* 70:5230.
- Bachmann, M. F., H. Schorle, R. Kuhn, W. Muller, H. Hengartner, R. M. Zinkernagel, and I. Horak. 1995. Antiviral immune responses in mice deficient for both interleukin-2 and interleukin-4. *J. Virol.* 69:4842.
- Fischer, J. E., J. E. Johnson, R. K. Kuli-Zade, T. R. Johnson, S. Aung, R. A. Parker, and B. S. Graham. 1997. Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. *J. Virol.* 71:8672.
- Mo, X. Y., M. Y. Sangster, R. A. Tripp, and P. C. Doherty. 1997. Modification of the Sendai virus-specific antibody and CD8⁺ T-cell responses in mice homozygous for disruption of the interleukin-4 gene. *J. Virol.* 71:2518.
- Hsu, D. H., R. de Waal Malefyt, D. F. Fiorentino, M. N. Dang, P. Vieira, J. de Vries, H. Spits, T. R. Mosmann, and K. W. Moore. 1990. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. *Science* 250:830.
- Kurilla, M. G., S. Swaminathan, R. M. Welsh, E. Kieff, and R. R. Brutkiewicz. 1993. Effects of virally expressed interleukin-10 on vaccinia virus infection in mice. *J. Virol.* 67:7623.
- Lin, M. T., D. R. Hinton, B. Parra, S. A. Stohman, and R. C. van der Veen. 1998. The role of IL-10 in mouse hepatitis virus-induced demyelinating encephalomyelitis. *Virology* 245:270.
- MacMicking, J., Q.-W. Xie, and C. Nathan. 1997. Nitric oxide and macrophage function. *Annu. Rev. Immunol.* 15:323.
- Karupiah, G., Q. W. Xie, R. M. Buller, C. Nathan, C. Duarte, and J. D. MacMicking. 1993. Inhibition of viral replication by interferon- γ -induced nitric oxide synthase. *Science* 261:1445.
- Adler, H., J. L. Beland, N. C. Del-Pan, L. Kobzik, J. P. Brewer, T. R. Martin, and I. J. Rimm. 1997. Suppression of herpes simplex virus type 1 (HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS2). *J. Exp. Med.* 185:1533.
- Mannick, J. B., K. Asano, K. Izumi, E. Kieff, and J. S. Stamler. 1994. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. *Cell* 79:1137.
- Lowenstein, C. J., S. L. Hill, A. Lafond-Walker, J. Wu, G. Allen, M. Landavere, N. R. Rose, and A. Herskowitz. 1996. Nitric oxide inhibits viral replication in murine myocarditis. *J. Clin. Invest.* 97:1837.

39. Karupiah, G., and N. Harris. 1995. Inhibition of viral replication by nitric oxide and its reversal by ferrous sulfate and tricarboxylic acid cycle metabolites. *J. Exp. Med.* 181:2171.
40. Rolph, M. S., W. B. Cowden, C. J. Medveczky, and I. A. Ramshaw. 1996. A recombinant vaccinia virus encoding inducible nitric oxide synthase is attenuated in vivo. *J. Virol.* 70:7678.
41. Rolph, M. S., I. A. Ramshaw, K. A. Rockett, J. Ruby, and W. B. Cowden. 1996. Nitric oxide production is increased during murine vaccinia virus infection, but may not be essential for virus clearance. *Virology* 217:470.
42. Alcami, A., and G. L. Smith. 1995. Cytokine receptors encoded by poxviruses: a lesson in cytokine biology. *Immunol. Today* 16:474.
43. Kopf, M., G. Le Gros, M. Bachmann, M. C. Lamers, H. Bluethmann, and G. Koller. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. *Nature* 362:245.
44. Kuhn, R., J. Lohler, D. Rennick, K. Rajewsky, and W. Muller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell* 75:263.
45. Dalton, D. K., M. S. Pitts, S. Keshav, I. S. Figari, A. Bradley, and T. A. Stewart. 1993. Multiple defects of immune cell function in mice with disrupted interferon- γ genes. *Science* 259:1739.
46. Magram, J., S. E. Connaughton, R. R. Warriar, D. M. Carvajal, C. Y. Wu, J. Ferrante, C. Stewart, W. Sarmiento, D. A. Faherty, and M. K. Gately. 1996. IL-12-deficient mice are defective in IFN- γ production and type 1 cytokine responses. *Immunity* 4:471.
47. MacMicking, J. D., C. Nathan, G. Hom, N. Chartrain, D. S. Fletcher, M. Trumbauer, K. Stevens, Q. W. Xie, K. Sokol, N. Hutchinson, et al. 1995. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. *Cell* 81:641.
48. Kohonen-Corish, M. R., N. J. King, C. E. Woodhams, and I. A. Ramshaw. 1990. Immunodeficient mice recover from infection with vaccinia virus expressing interferon- γ . *Eur. J. Immunol.* 20:157.
49. Barner, M., M. Mohrs, F. Brombacher, and M. Kopf. 1998. Differences between IL-4R α -deficient and IL-4-deficient mice reveal a role for IL-13 in the regulation of Th2 responses. *Curr. Biol.* 8:669.
50. Noben-Trauth, N., L. D. Shultz, F. Brombacher, J. F. Urban, Jr., H. Gu, and W. E. Paul. 1997. An interleukin 4 (IL-4)-independent pathway for CD4⁺ T cell IL-4 production is revealed in IL-4 receptor-deficient mice. *Proc. Natl. Acad. Sci. USA* 94:10838.
51. Kaplan, M. H., U. Schindler, S. T. Smiley, and M. J. Grusby. 1996. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. *Immunity* 4:313.
52. Takeda, K., T. Tanaka, W. Shi, M. Matsumoto, M. Minami, S. Kashiwamura, K. Nakanishi, N. Yoshida, T. Kishimoto, and S. Akira. 1996. Essential role of Stat6 in IL-4 signalling. *Nature* 380:627.
53. Shimoda, K., J. van Deursen, M. Y. Sangster, S. R. Sarawar, R. T. Carson, R. A. Tripp, C. Chu, F. W. Quelle, T. Nosaka, D. A. Vignali, et al. 1996. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. *Nature* 380:630.
54. Wu, C., J. Ferrante, M. K. Gately, and J. Magram. 1997. Characterization of IL-12 receptor β chain (IL-12R β 1)-deficient mice: IL-12R β 1 is an essential component of the functional mouse IL-12 receptor. *J. Immunol.* 159:1658.
55. Kaplan, M. H., Y. L. Sun, T. Hoey, and M. J. Grusby. 1996. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. *Nature* 382:174.
56. Thierfelder, W. E., J. M. van Deursen, K. Yamamoto, R. A. Tripp, S. R. Sarawar, R. T. Carson, M. Y. Sangster, D. A. Vignali, P. C. Doherty, G. C. Grosveld, and J. N. Ihle. 1996. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. *Nature* 382:171.
57. Ramshaw, I. A., A. J. Ramsay, G. Karupiah, M. S. Rolph, S. Mahalingam, and J. C. Ruby. 1997. Cytokines and immunity to viral infections. *Immunol. Rev.* 159:119.
58. Graham, M. B., D. K. Dalton, D. Giltinan, V. L. Braciale, T. A. Stewart, and T. J. Braciale. 1993. Response to influenza infection in mice with a targeted disruption in the interferon γ gene. *J. Exp. Med.* 178:1725.
59. Huang, S., W. Hendriks, A. Althage, S. Hemmi, H. Bluethmann, R. Kamijo, J. Vilcek, R. M. Zinkernagel, and M. Aguet. 1993. Immune response in mice that lack the interferon- γ receptor. *Science* 259:1742.
60. Karupiah, G., T. N. Fredrickson, K. L. Holmes, L. H. Khairallah, and R. M. Buller. 1993. Importance of interferons in recovery from mousepox. *J. Virol.* 67:4214.
61. Lucin, P., I. Pavic, B. Polic, S. Jonjic, and U. Koszinowski. 1992. Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. *J. Virol.* 66:1977.
62. Lucchiari, M. A., M. Modolell, K. Eichmann, and C. A. Pereira. 1992. In vivo depletion of interferon- γ leads to susceptibility of A/J mice to mouse hepatitis virus 3 infection. *Immunobiology* 185:475.
63. Schijns, V. E., B. L. Haagmans, E. O. Rijke, S. Huang, M. Aguet, and M. C. Horzinek. 1994. IFN- γ receptor-deficient mice generate antiviral Th1-characteristic cytokine profiles but altered antibody responses. *J. Immunol.* 153:2029.
64. Sarawar, S. R., R. D. Cardin, J. W. Brooks, M. Mehrpooya, A. M. Hamilton Easton, X. Y. Mo, and P. C. Doherty. 1997. Gamma interferon is not essential for recovery from acute infection with murine gammaherpesvirus 68. *J. Virol.* 71:3916.
65. van den Broek, M. F., U. Muller, S. Huang, M. Aguet, and R. M. Zinkernagel. 1995. Antiviral defense in mice lacking both $\alpha\beta$ and γ interferon receptors. *J. Virol.* 69:4792.
66. Orange, J. S., T. P. Salazar-Mather, S. M. Opal, R. L. Spencer, A. H. Miller, B. S. McEwen, and C. A. Biron. 1995. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. *J. Exp. Med.* 181:901.
67. Bi, Z., P. Quandt, T. Komatsu, M. Barna, and C. S. Reiss. 1995. IL-12 promotes enhanced recovery from vesicular stomatitis virus infection of the central nervous system. *J. Immunol.* 155:5684.
68. Trinchieri, G. 1998. Immunobiology of interleukin-12. *Immunol. Res.* 17:269.
69. Morris, S. C., K. B. Madden, J. J. Adamovics, W. C. Gause, B. R. Hubbard, M. K. Gately, and F. D. Finkelman. 1994. Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. *J. Immunol.* 152:1047.
70. Taylor, A. P., and H. W. Murray. 1997. Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon- γ gene-disrupted mice. *J. Exp. Med.* 185:1231.
71. Bhardwaj, N., R. A. Seder, A. Reddy, and M. V. Feldman. 1996. IL-12 in conjunction with dendritic cells enhances antiviral CD8⁺ CTL responses in vitro. *J. Clin. Invest.* 98:715.
72. Orange, J. S., and C. A. Biron. 1996. An absolute and restricted requirement for IL-12 in natural killer cell IFN- γ production and antiviral defense: studies of natural killer and T cell responses in contrasting viral infections. *J. Immunol.* 156:1138.
73. Kagi, D., P. Seiler, J. Pavlovic, B. Ledermann, K. Burki, R. M. Zinkernagel, and H. Hengartner. 1995. The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. *Eur. J. Immunol.* 25:3256.
74. D'Andrea, A., M. Aste-Amezaga, N. M. Valiante, X. Ma, M. Kubin, and G. Trinchieri. 1993. Interleukin 10 (IL-10) inhibits human lymphocyte interferon- γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. *J. Exp. Med.* 178:1041.
75. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufer, E. Kampgen, N. Romani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. [Published erratum appears in 1996 *J. Exp. Med.* 184:1591.] *J. Exp. Med.* 184:741.
76. Gazzinelli, R. T., M. Wysocka, S. Hieny, T. Schariton-Kersten, A. Cheever, R. Kuhn, W. Muller, G. Trinchieri, and A. Sher. 1996. In the absence of endogenous IL-10, mice acutely infected with *Toxoplasma gondii* succumb to a lethal immune response dependent on CD4⁺ T cells and accompanied by overproduction of IL-12, IFN- γ and TNF- α . *J. Immunol.* 157:798.
77. Dai, W. J., G. Kohler, and F. Brombacher. 1997. Both innate and acquired immunity to *Listeria monocytogenes* infection are increased in IL-10-deficient mice. *J. Immunol.* 158:2259.
78. Kopf, M., H. Baumann, G. Freer, M. Freudenberg, M. Lamers, T. Kishimoto, R. Zinkernagel, H. Bluethmann, and G. Kohler. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. *Nature* 368:339.
79. Mattner, F., J. Magram, J. Ferrante, P. Launois, K. Di Padova, R. Behin, M. K. Gately, J. A. Louis, and G. Alber. 1996. Genetically resistant mice lacking interleukin-12 are susceptible to infection with *Leishmania major* and mount a polarized Th2 cell response. *Eur. J. Immunol.* 26:1553.
80. Coutelier, J. P., J. Van Broeck, and S. F. Wolf. 1995. Interleukin-12 gene expression after viral infection in the mouse. *J. Virol.* 69:1955.
81. Kanangat, S., J. Thomas, S. Gangappa, J. S. Babu, and B. T. Rouse. 1996. Herpes simplex virus type 1-mediated up-regulation of IL-12 (p40) mRNA expression: implications in immunopathogenesis and protection. *J. Immunol.* 156:1110.
82. Orange, J. S., and C. A. Biron. 1996. Characterization of early IL-12, IFN- $\alpha\beta$, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. *J. Immunol.* 156:4746.
83. Sad, S., R. Marcotte, and T. R. Mosmann. 1995. Cytokine-induced differentiation of precursor mouse CD8⁺ T cells into cytotoxic CD8⁺ T cells secreting Th1 or Th2 cytokines. *Immunity* 2:271.
84. Erard, F., M. T. Wild, S. J. Garcia, and G. G. Le. 1993. Switch of CD8 T cells to noncytolytic CD8⁻CD4⁻ cells that make TH2 cytokines and help B cells. *Science* 260:1802.
85. Tang, Y. W., and B. S. Graham. 1994. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. *J. Clin. Invest.* 94:1953.
86. Karupiah, G., R. V. Blanden, and I. A. Ramshaw. 1990. Interferon γ is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection. *J. Exp. Med.* 172:1495.
87. Sambhi, S. K., M. R. Kohonen-Corish, and I. A. Ramshaw. 1991. Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. *Proc. Natl. Acad. Sci. USA* 88:4025.
88. Ruby, J., H. Bluethmann, M. Aguet, and I. A. Ramshaw. 1995. CD40 ligand has potent antiviral activity. *Nat. Med.* 1:437.
89. Oxenius, A., K. A. Campbell, C. R. Maliszewski, T. Kishimoto, H. Kikutani, H. Hengartner, R. M. Zinkernagel, and M. F. Bachmann. 1996. CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4⁺ T cell functions. *J. Exp. Med.* 183:2209.